Celldex Therapeutics (CLDX) Operating Income (2010 - 2026)

Celldex Therapeutics' Operating Income history runs 17 years deep, the most recent figure standing at -$84.4 million for Q1 2026.

• On a quarterly basis, Operating Income fell 34.58% year-over-year to -$84.4 million in Q1 2026; TTM through Mar 2026 was -$309.1 million, a 42.29% decrease from a year earlier, with the FY2025 full-year figure at -$287.4 million, down 47.31% from the prior year.
• Operating Income improved to -$84.4 million in Q1 2026 per CLDX's latest filing, from -$87.2 million in the prior quarter.
• Across five years, Operating Income topped out at -$23.3 million in Q1 2022 and bottomed at -$87.2 million in Q4 2025.
• The 5-year median for Operating Income is -$46.3 million (2024), against an average of -$49.2 million.
• Across the five-year window, Operating Income tumbled 170.8% in 2022 and rose 8.77% in 2023, its largest moves.
• Year by year, Operating Income stood at -$27.9 million in 2022, then plunged by 70.8% to -$47.6 million in 2023, then decreased by 17.64% to -$56.0 million in 2024, then sank by 55.56% to -$87.2 million in 2025, then gained by 3.12% to -$84.4 million in 2026.
• Per Business Quant, the three latest CLDX Operating Income figures stand at -$84.4 million (Q1 2026), -$87.2 million (Q4 2025), and -$73.6 million (Q3 2025).